Retroviral insertional mutagenesis is a powerful tool for identifying putative cancer genes in mice. To uncover the regulatory mechanisms by which common insertion loci affect downstream processes, we supplemented genotyping data with genome-wide mRNA expression profiling data for 97 tumors induced by retroviral insertional mutagenesis. We developed locus expression signature analysis, an algorithm to construct and interpret the differential gene expression signature associated with each common insertion locus. Comparing locus expression signatures to promoter affinity profiles allowed us to build a detailed map of transcription factors whose protein-level regulatory activity is modulated by a particular locus. We also predicted a large set of drugs that might mitigate the effect of the insertion on tumorigenesis. Taken together, our results demonstrate the potential of a locus-specific signature approach for identifying mammalian regulatory mechanisms in a cancer context. genome-wide expression profiling | transcription factor activity | gene regulatory network | computational cancer biology | data integration M ouse retroviral insertional mutagenesis has been used as an efficient tool for identification of causal mutations in cancer (1). Such oncogenic mutations may either cause alteration of a gene product or influence the expression levels of one or more genes surrounding the insertion. More than 10,000 common insertion sites (CISs) at which retroviral insertions are found in multiple tumors have been identified (2). Methods exist that predict which genes are affected by insertions based on information such as orientation and position (3). However, it is not always straightforward to determine which genetic lesions near a CIS are playing a causal role. Moreover, these approaches are based on gene annotation and do not use or provide functional evidence. Analyzing the mRNA expression level of the genes near the insertion site is often not sufficient, as the lesion may exert its effect only at the posttranslational level. Furthermore, retroviral insertional mutagenesis screens alone rarely elucidate the regulatory mechanisms that drive tumorigenesis. These limitations highlight the need for new approaches that can integrate the genetic data with functional genomics data and other information to identify causal genes and regulatory mechanisms underlying cancer.
Retroviral insertional mutagenesis is a powerful tool for identifying putative cancer genes in mice. To uncover the regulatory mechanisms by which common insertion loci affect downstream processes, we supplemented genotyping data with genome-wide mRNA expression profiling data for 97 tumors induced by retroviral insertional mutagenesis. We developed locus expression signature analysis, an algorithm to construct and interpret the differential gene expression signature associated with each common insertion locus. Comparing locus expression signatures to promoter affinity profiles allowed us to build a detailed map of transcription factors whose protein-level regulatory activity is modulated by a particular locus. We also predicted a large set of drugs that might mitigate the effect of the insertion on tumorigenesis. Taken together, our results demonstrate the potential of a locus-specific signature approach for identifying mammalian regulatory mechanisms in a cancer context. genome-wide expression profiling | transcription factor activity | gene regulatory network | computational cancer biology | data integration M ouse retroviral insertional mutagenesis has been used as an efficient tool for identification of causal mutations in cancer (1) . Such oncogenic mutations may either cause alteration of a gene product or influence the expression levels of one or more genes surrounding the insertion. More than 10,000 common insertion sites (CISs) at which retroviral insertions are found in multiple tumors have been identified (2) . Methods exist that predict which genes are affected by insertions based on information such as orientation and position (3). However, it is not always straightforward to determine which genetic lesions near a CIS are playing a causal role. Moreover, these approaches are based on gene annotation and do not use or provide functional evidence. Analyzing the mRNA expression level of the genes near the insertion site is often not sufficient, as the lesion may exert its effect only at the posttranslational level. Furthermore, retroviral insertional mutagenesis screens alone rarely elucidate the regulatory mechanisms that drive tumorigenesis. These limitations highlight the need for new approaches that can integrate the genetic data with functional genomics data and other information to identify causal genes and regulatory mechanisms underlying cancer.
Here, we carried out genome-wide expression profiling in a set of tumors induced by retroviral insertional mutagenesis. We also present a computational approach, locus expression signature analysis (LESA), that first defines and then analyzes the genome-wide mRNA expression response induced by the putative causal gene near the insertion locus. We analyzed genome-wide expression profiles for a panel of splenic tumors induced by retroviral insertional mutagenesis (3). To identify regulatory mechanisms underlying tumorigenesis, we hypothesized that gene expression is affected by insertional mutations through the regulation by sequence specific transcription factors (TFs). We construct a map that connects each insertion locus with the TFs whose regulatory activity is affected by it. This map contains both known and putative new associations. LESA also predicted a large set of drugs that might mitigate the effect of the insertion on tumorigenesis. Together, our results demonstrate the ability of LESA to identify candidate regulatory mechanisms in cancer.
Results
Identifying Common Insertion Sites. Many insertion regions are tagged in multiple independent tumors. To identify CISs, i.e., regions in the genome that are significantly more frequently mutated by insertions than would be expected by chance, we used a statistical framework based on Gaussian kernel convolution (GKC), which estimates a smoothed density distribution of inserts over the entire genome (4) . Next, we applied rule-based mapping (RBM), which maps individual insertions to target genes based on orientation-dependent windows and information regarding repetitive occurrence of insertions at a given locus across tumors (3). We identified 87 insertion sites and assigned a potential modulator gene that most likely generates the tumors in collaboration with the loss of tumor protein p53 and an alternative open reading frame of INK4A-ARF locus ( p19 ARF ). For further analysis, we focused on 13 insertion loci that occur in at least 10 tumors. The loci include known oncogenes such as transmembrane receptor NOTCH1, myelocytomatosis oncogene Significance Each individual tumor harbors a unique combination of genetic lesions, which together are responsible for the aberrant behavior of its cells. Cancer-causing viruses have been used in mice to systematically sample this genetic diversity. Corresponding changes in global gene expression can be monitored using high-throughput technology. In this study, we present a computational strategy that integrates information at the genetic and molecular level to construct a genome-wide signature that captures the effect of an individual genetic lesion on the gene regulatory network of the cell. We show how these signatures can be exploited to gain insight into the processes and regulatory pathways perturbed by each lesion and suggest drugs that can counteract its effect.
(MYC), and v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) (MYCN).
LESA. Our hypothesis is that an insertional mutation perturbs the function or expression level of the proximal causal gene contributing to tumorigenesis in collaboration with loss of p53 or p19 ARF , and the perturbed causal gene in turn influences the function or expression level of downstream target genes in the signaling pathway. Therefore, the contribution to tumorigenesis by a causal mutation might have a characteristic gene expression signature associated with it. Based on this assumption, we inferred locus expression signatures (LESs) representing the average difference in mRNA expression between the tumors carrying insertions at a particular locus and all other tumors (Fig. 1) .
In a previous analysis of the insertion data per se (5), insertion loci and genetic background ( p19
, and WT) were found to co-occur across tumors (Fig. S1A) , which is an indication for collaboration between these lesions in driving tumorigenesis. To deal with this dependency, we used a multiple linear regression to explain the variation in mRNA expression level for each gene in terms of the pattern of insertions in each tumor (Fig. 1) . The coefficients from the model fit for a particular gene were used to define one row of a matrix of LESs. Each column of this matrix represents the average genome-wide differential mRNA expression response to insertion at a particular locus. For each insertion locus, we compared the variance of the signature value across all genes with its null distribution (SI Materials and Methods). We found that for most loci the information contained in their signature is highly statistically significant (Fig. S1C ). Furthermore, a significant fraction (up to 22%) of the variance of expression levels across tumors can be accounted for as a linear combination of locus expression signatures (Fig. S1D ). This observation encouraged us to dissect the regulatory mechanisms that give rise to these signatures.
Regulation of Individual Genes as Identified by LESA. The absolute value of the LES is highest for genes whose expression level is most strongly affected by the associated genetic mutation. As expected for the signatures we inferred for the contribution of the p53 −/− and p19 ARF−/− deletion backgrounds, respectively, Trp53 had the most negative value in the p53 signature, whereas the p19 ARF isoform cyclin-dependent kinase inhibitor 2A (Cdkn2a) showed one of the most negative p19
ARF signature values (Fig. 2) . We also found an association between the loss of p53 and the increase of Cdkn2a expression, suggesting a feedback mechanism compensating for the loss of p53.
Among the remaining signatures, i.e., those associated with common insertion loci, we detected a strong cis-association for NOTCH1, RAS guanyl releasing protein 1 (RASGRP1), growth factor independent 1 (GFI1), and related RAS viral (r-ras) oncogene homolog 2 (RRAS2), with retroviral insertions either increasing or decreasing the mRNA expression level of the gene designated as their primary target ( Fig. 2 and Table S1 ). To analyze the extent to which an insertion could have a wider local effect, we inspected the expression signature values near the insertion locus. The expression of the gene proximal to cyclin D3 (CCND3) and runt related transcription factor 1 (RUNX1) was induced by retroviral insertion (Fig. 2) . In other cases, insertions may affect genes at the protein level with no apparent change at the mRNA level (as exemplified by the MYC expression signature in Fig. S2A ), resulting in the change in the transcription level of functionally related or known direct target genes. Examples in Table S1 include the CCND3 and MYC loci, both of which influence the mRNA expression level of the Ccnd2 gene. Unexpectedly, we found that the gene a disintegrin and metallopeptidase domain 19 (Adam19) has a high NOTCH1 signature value, suggesting a positive feedback loop: Adam19 is a metalloprotease known to activate Notch1 by cleaving it (6).
Expression Signatures Can Elucidate the Biological Functions Affected
by Insertions at Specific Loci. To explore the functional significance of the locus expression signatures, we used gene ontology (GO) terms to identify the biological process, molecular function, and cellular component categories enriched in each locus expression signature. We compared the distribution of the locus expression signature values in each particular GO category with that of the remaining genes using the Wilcoxon-Mann-Whitney (WMW) test. Because the GO categories are hierarchically organized, with overlapping gene sets that are mutually redundant, we used a forward selection scheme (7) to select a nonredundant set of significantly associated GO categories.
The resulting functional map provides several useful insights ( Fig. 3 and Fig. S3 ). First, the GO categories associated with the p53 −/− effect on expression are a subset of those associated with the p19 ARF−/− background. For example, the "DNA repair" genes are suppressed in tumors lacking either p19 ARF or p53, consistent with the known role of these genes as activators of DNA repair (8) . By contrast, the "M phase of mitotic cell cycle" genes are enriched only in the p19 ARF expression signature (Fig. S2B ). This observation agrees with the fact that, although . The contribution to tumorigenesis by a causal mutation might have a characteristic gene expression signature associated with it. Based on this assumption, we inferred locaus expression signatures (LESs) representing the average difference in mRNA expression between the tumors carrying insertions at a particular locus and all other tumors using common insertion sites data and gene expression data for each tumor. These LESs are used for further analyses including finding significant GO associations, changes in protein-level TF activities, or correlations with drug response signatures. 
p19
ARF acts upstream of p53 by enhancing p53 activity (9) , it may also suppress tumorigenesis independently of p53 (10) .
"Lysosome" genes are significantly associated with the p19 ARF , MYCN, genomic sequence AC153556, and mediator complex subunit 20 (MED20)/CCND3 signatures. The lysosome controls cell death, and lysosomal alterations are common in cancer cells (11) . The mechanism mediating the effect of these insertions on the expression level of lysosomal genes is not clear.
In addition, we detected association with "mitochondrion" genes for several loci (p19 ARF , NOTCH1, MYB, MYCN, and MYC). Interestingly, p19 ARF and Myc are both known to regulate apoptosis via the release of cytochrome c from mitochondria (12) . Several genes related to mitochondria-dependent apoptosis, including Hspd1 (13), Bnip3l (14) , and cytochrome c oxidase genes Cox7a2 and Cox6c, have among the lowest MYB expression signature values among genes within this category, suggesting a role for Myb as a mitochondria-dependent apoptosis regulator.
Furthermore, we found locus-specific GO categories such as "T-cell differentiation" for RASGRP1, consistent with the role of Rasgrp1 in T-cell signaling (15) , and "microtubule-based process" for RRAS2, supporting its role in the regulation of cytoskeleton and its participation in related function such as adhesion, migration, and invasion (16) .
Our functional analysis revealed that, by and large, the insertion loci fall into two major groups, with opposite characteristics and opposite effects on expression across multiple pathways: (i) MYCNlike (e.g., MYCN, RRAS2, and MED20/CCND3), with positive associations with GO categories such as RNA processing, mitochondria, and DNA repair, and (ii) p19 ARF -like (e.g., p19 ARF , p53, and GFI1), with a positive association with the lysosome in particular. This observation implies that insertions either help or oppose each other in enhancing or abrogating tumorigenesis. The downstream consequences of loss of the tumor suppressor gene p53 or p19 ARF seem to be exacerbated by insertions near loci such as MYCN, RRAS2, and MED20/CCND3, but mitigated by insertion near GFI1. Indeed, we found a strong negative correlation between insertion near MYCN and mRNA expression of the MYC gene (t-value = 19.94, P = 8.9 × 10 −24
), whose enhanced protein expression contributes to almost every aspect of tumor cell biology (17) .
Detecting Changes in Protein-Level TF Activity Associated with Mutations. Having surveyed the gene function landscape associated with each insertion locus based on its genome-wide expression signature, we next wished to identify the specific transacting regulatory mechanisms underlying their influence on the formation of tumors (Fig. 4A) . We previously demonstrated that when the binding specificity of a TF is known (in the form of a weight matrix), quantitative changes in its regulatory activity can be inferred by performing genome-wide linear regression of a single genome-wide differential mRNA expression profile on the predicted total in vitro binding affinity of cis-regulatory regions (18) , the regression coefficients corresponding to changes in TF activity at the protein level. It is important to note that the mRNA expression level of the gene encoding the TF is not considered in this analysis; indeed, the activity of many TFs is modulated at the posttranslational level through covalent modifications such as (de) phosphorylation, which in turn can shift the subcellular distribution of the TF protein from cytoplasmic to nuclear or vice versa.
Here, we used a compendium of position weight matrices (PWMs) for 130 vertebrate TFs from the JASPAR database (19) and 11 family-level PWMs for well-characterized structural TF families (20) . We converted each PWM to an approximate position-specific affinity matrix (PSAM) by assuming base frequencies to be proportional to relative binding affinities at each position within the binding site (21) .
Not only did we assume the contribution to the transcription rate by any particular binding site to be proportional to its binding affinity, we also assumed it to decay exponentially with distance from the transcriptional start site (TSS). The corresponding length scale parameter was inferred from the data (see Materials and Methods and SI Materials and Methods for details). We found a relatively strong correlation between the locus expression signature value for each gene and the percentage of A, C, G, and T in its regulatory region (Fig. S4) . To avoid confounding due to these low-complexity signals, we inferred TF activities from the residuals of a linear regression of the signature on base composition (Materials and Methods and SI Materials and Methods). Despite the fact that using a weight matrix to represent the target specificity of a TF has some limitations, especially when it comes to distinguishing between TFs with closely similar sequence specificity, our method allowed us to make a number of interesting observations. Controlling for multiple testingusing stringent P value thresholds of 1.0 × 10 −6 and 7.9 × 10 −10
for familial and individual TF-locus associations, respectively, corresponding to a false discovery rate (FDR) of 0.1%-we identified a total of 22 TF-locus associations (Fig. 4B) . These associations include known relationships, such as that of insertions at the p19 ARF and MYCN loci activating reticuloendotheliosis oncogene (REL) family members NFKB1, nuclear factor of kappa light polypeptide gene enhancer (NF-κB), RELA, and REL (P = 9.2 × 10 −13 and 2.5 × 10 −11
, respectively), which are known to promote the oncogenic phenotype such as angiogenesis, proliferation, and invasion/metagenesis (22) ; Mycn is also known to suppress the mRNA expression level of the p50 subunit of NF-κB (23). Our algorithm also detected that one or more members of the Trp family of transcription factors (which includes Myb) may be responsible for the transcriptional response to insertion at the MYB locus. Furthermore, the activity of the basic helix-loop-helix (bHLH) family is significantly affected by the loss of p53, as well as viral insertion near the MYC, MYCN, or PVT1 locus (Fig. 4B) . Some TFs are modulated by multiple mutations, such as E2F transcription factor 1 (E2F1), which mediates the transcriptional response to both the p19 ARF background and to insertion at the CCND3 locus (P = 1.8 × 10 −18 and 1.2 × 10 −10 , respectively), consistent with the previous observation that human ARF binds to E2F1 to inhibit its transcriptional activity (24) . Other TFs only respond to insertion at one of the loci in our panel, such as the factor Pou5f1 to the NOTCH1 locus. Furthermore, the association found between the Myc locus and the trans-acting transcription factor 1 (SP1) is consistent with a previous observation of cooperative transcriptional activation by the Myc and SP1 proteins (25, 26) .
Insertions at the MYC Locus Modulate the Activity of c-Myc at the
Protein Level and Not the Transcript Level. Of particular interest among our findings was the association between predicted binding affinity for Myc and the expression response to insertions at the MYC locus. Because there is no significant correlation between Myc mRNA expression level and the presence of an insertion at the MYC locus, insertions near MYC are likely to act posttranscriptionally. To validate our findings, we analyzed gene expression profiles obtained after Myc inactivation using doxycycline treatment (27) . Analyzing the genome-wide profile of differential mRNA expression between Myc-inactivated and mocktreated cells in exactly the same way as the MYC locus expression signature (Fig. S5) , we found significant differential activity both for bHLH factors at the family level and for the bHLH factor Myc at the single TF level.
Relating Drug Response to Locus Expression Signatures. There is a close analogy between how a viral insertion and a drug affect the cell state at various levels, including that of the transcriptome (Fig. 5A) . In fact, our study could be viewed as an attempt to uncover the mode of action of viral insertion at a specific locus. To systematically search for drugs that might move the cell state in a direction opposite to the change in cell state caused by to a specific mutation, we analyzed data from the Connectivity Map, encompassing 7,000 genome-wide expression responses to 1,309 different compounds (28) . We analyzed the genome-wide linear correlation between each locus expression signature and each drug response profile. A negative correlation between locus signature and drug response indicates that the drug might mitigate the effect of the insertion on tumorigenesis (therapeutic); a positive correlation indicates that the drug might exacerbate it.
We found a total of 281 significant drug-locus relationships at an FDR of 1% (Fig. S6) . Of 15 loci, 10 were significantly associated with at least one significant candidate therapeutic drug. Interestingly, even though the overall patterns of drug association are similar for MYC and MYCN, these loci each had specific drug associations. The MYC signature has a significant negative correlation with the response to phosphatidylinositol 3-kinase (PI3K) inhibitors (i.e., wortmannin and LY-294002), whereas the response to histone deacetylases (i.e., valproic acid, trichostatin A, vorinostat, MS-275, scriptaid, and cyclic tetrapeptide HC toxin) significantly antagonizes the MYCN signature (blue and red box, respectively, in Fig. S6 ). Furthermore, our analysis predicts tumors with insertions at mmu-mir-106a to be responsive to topoisomerase inhibitors (i.e., camptothecin, mitoxantrone, doxorubicin, daunorubicin, and irinotecan), a well-known class of anticancer drugs (green boxes in Fig. S6 ). Taken together, our results suggest a strategy for predicting drug responsiveness from knowledge of the genotype of an individual tumor.
To investigate additional pathways through which drug treatments perturb TFs to reprogram cellular state, we derived a detailed network containing drugs that perturb the activities of TFs, which in turn potentially mitigate the effect of the insertional mutation. For each negatively associated drug/locus combination, we analyzed the correlation of drug responses and locus expression signatures with TF binding affinities to construct TF networks whose activities are perturbed both by drug treatment and insertion. This network model suggests detailed mechanisms by which a tumor with a specific insertional mutation could be responsive to a particular cancer drug. Our results include known relationships between drugs and TFs ( Fig. 5B ; all significant drug-TF-locus associations we predict are shown in Fig. S7 ). For example, our prediction that sirolimus, which functions similarly to rapamycin, and LY-294002, which functions as an inhibitor of PI3K (both antagonize the MYC insertion signature potentially via Myc transcription activity), is consistent with previous observations (29) . Additionally, rottlerin has indeed been shown to undo the effect of insertion near MYCN through the activity of REL family factors including NF-κB (30, 31) .
Relating Human Mutation Expression Signatures to Mouse Locus
Expression Signatures. To compare the expression signatures of mouse insertion loci with those of the human somatic mutation in tumors, we analyzed genome-wide expression profiles and somatic mutation data of 194 acute myeloid leukemia tumors from the cancer genome atlas (TCGA), motivated by the relatively close relatedness between leukemia and lymphoma. Among the human orthologs of p53, p19 ARF , and the 13 putative target genes of the common insertion loci in our mouse tumor panel, only RUNX1 and TP53 had at least one nonsilent mutation in at least 10 human tumor samples (corresponding to a 5% frequency across human tumor samples). For these two genes, we first constructed a genome-wide transcriptional response signature associated with their mutation, in a manner analogous to how we constructed the mouse LESs (SI Materials and Methods). Next, we compared the two human signatures with all mouse signatures by computing pairwise Pearson correlations. Encouragingly, we found that the human TP53 mutation signature was most strongly associated with the mouse p53 expression signatures ( Fig. S8A ; P < 10
−16
). Although for the human RUNX1 mutation signature we observed no significant correlation with the mouse RUNX1 insertion signature, a strong correlation did exist with the mouse p19 ARF insertion signature (Fig. S8B) . This observation suggests a close relationship between RUNX1 and p19 ARF in the development of leukemia or lymphoma, consistent with a previous study (32) . Taken together, these results support the usefulness of our locus expression signatures, both those based on mouse insertional mutagenesis and those based on mutations observed in human cancer.
Discussion
The LESA approach presented here allows us to exploit the genome-wide transcriptional response to a change in the structure and/or expression level of the causal gene near the insertion locus, even if the latter is initially unknown. Systematic application of LESA uncovered a large number of connections between common insertion loci and their downstream gene regulatory mechanisms-some of which were known and many of which are novel predictions. In the first place, our results include many locus-TF associations in which the regulatory activity of a particular TFs or TF family is modulated by viral insertion at a particular locus. By construction, these associations are causal (the insertion changes expression levels and not the other way around) and functional (the signature represents changes in mRNA expression caused by the insertion). Our method fully accounts for posttranslational regulation of TF activity at the protein level. For example, we found Myc activity at the protein level to change in response insertions near the MYC locus, even though the mRNA expression level of the MYC gene does not change. Furthermore, by relating our locus signatures directly to drug response profiles from the Connectivity Map, we were able to identify drugs that might specifically counteract the deregulatory effect of mutations at particular loci. A previous study (33) integrated drug response profiles with expression signatures for human disease to predict novel therapeutic indication.
The mammalian genome is a complex landscape: some regions are very gene rich, whereas others are devoid of genes (34) (35) (36) . This variation in gene density is linked to large-scale variation in DNA base composition (35, 36) . GC content in turn is positively correlated with expression level (37) . To capture any such effects of low sequence complexity, we considered DNA base composition as well as CpG content. We detected a high correlation between sequence composition and signature value for several loci including MYB, AC153556, and mmu-mir-106a∼363. For most loci, the region downstream of the TSS showed higher correlations than that upstream of the TSS. At the same time, loci such as MYCN, MYC, and MED20/CCND3 do not show any correlation with low-complexity sequence signals (Fig. S4) . The mechanism underlying these observations is not clear, and it would be interesting to further investigate them. To avoid confounding in our TF-centric analysis, we removed the low-complexity sequence effect in our analysis.
In mammals, many functional regulatory sites occur outside the proximal promoter (38) , and distal binding events up to 1 Mb away from the TSS have been shown to contribute to p300 occupancy (39) . How the contribution of binding sites to transcriptional control depends on its proximity to the TSS has been previously quantified (40) . We considered the sequence 200-kb upstream and downstream from the TSS as the cis-regulatory region. However, to allow for variable relationships between binding position and transcriptional control, we used TF-specific length scale parameters and fit these by maximizing the correlation between the weighted TF affinity profiling and the locus expression signature.
Taken together, our analyses have yielded a more comprehensive and detailed view of the oncogenic signaling networks and cis-regulatory mechanisms underlying tumorigenesis.
Materials and Methods
Gene Expression Data. Gene expression data were collected using Illumina MouseWG6-V2 beadchips and normalized using variance-stabilizing transformation (VST) and robust spline normalization (RSN) (41) . Illumina probes with no corresponding RefSeq ID were discarded, leaving 45,281 measurements. Averaging over probes mapping to the same RefSeq ID resulted in expression values for 19,010 genes.
Common Insertion Loci. The effect of viral insertions on their nearby targets is dependent on the relative position and orientation of the target transcript, as well as the orientation of the viral integration. To exploit this context information, we used a rule-based mapping (RBM) procedure (3). RBM assigns each insertion to one or more putative target transcripts based on a set of rules that were distilled from literature. The unique list of transcripts that results from this procedure is used to generate a binary profile that, for each tumor, indicates if a transcript is a putative target or not. We observed that for proximal transcripts the same binary profile frequently results. These transcripts were therefore treated as a single profile. Only transcript-insertion associations found in at least three tumors were considered in our analysis.
LESA. The variation in relative mRNA expression level across all tumors (represented as the log2-ratio relative to the mean across all tumors) was analyzed independently for each gene. To obtain LES values across all loci for a given gene, we performed ANOVA for the mRNA expression in terms of background genotype and insertion status at all loci considered, by fitting the following multivariate linear model:
Here, A gt represents the relative mRNA expression level for tumor t and gene g. B t,p19 ARF p19 and B t,p53 (taking values 0 or 1) indicate whether the genetic background of tumor t is p19 ARF−/− and p53 −/− , respectively, whereas I mt indicates whether an insertion was present at locus m in tumor t. After this analysis was completed for all genes, the expression signature for each background and for each viral insertion locus was constructed by combining the values of the pertinent regression coefficient β as a vector across all genes.
Forward Selection of GO Categories. Functional annotation of genes in terms of GO categories was performed using a variation of the T-profiler algorithm (7), including an iterative procedure to select a nonredundant set of gene sets from those that have a significantly different expression distribution from the other genes (see SI Materials and Methods for details).
Weight Matrices. TFs from the same structural family tend to bind to similar DNA target sequences (42) . Our analysis explicitly recognizes that it is often not possible to implicate a specific TF based on its binding specificity alone. The JASPAR database (19) contains models at the level of structural families with the shared DNA binding structures (20) . We downloaded 11 PWMs representing a distinct TF family from the JASPAR FAM database, as well as 130 PWMs that are supposed to represent individual TFs from the JASPAR CORE database.
TF Binding Affinity Profiles. The collection of position-specific affinity matrices or PSAMs (21) converted from PWMs was used to compute relative affinities for all putative individual binding sites in the genomic region from 200 kb upstream to 200 kb downstream of the TSS of each gene (see SI Materials and Methods for details). To obtain a total weighted upstream affinity for a given value of the regulatory scale parameter λ, we summed the affinity of all upstream binding sites using a weight exp(−d/λ), where d is the (absolute) distance of a given binding site from the TSS (see SI Materials and Methods for details). A total downstream affinity was computed in an analogous manner.
Mapping Locus-to-TF Network Connectivity. To treat the attribution of a regulatory role to TFs with similar sequence specificity in a conservative manner, we applied a two-step procedure. First, we performed multiple linear regression of low-complexity signal-corrected LES values (see SI Materials and Methods for details) on the weighted binding affinities for each TF family. Next, the residuals from this fit were regressed on affinity profiles for the individual TF. We computed P values using ordinary linear regression. Statistical significance was determined by performing 1,000 independent random permutation of for each gene. A 0.1% FDR for family-level and individual PSAMs corresponded to P <1.0 × 10 −6 and <7.9 × 10 −10
, respectively.
Mapping Drug-Locus Associations. Genome-wide mRNA expression data for cultured human cells treated with bioactive small molecules were downloaded from the Connectivity Map website (www.broadinstitute.org/cmap/) (28) . This collection contains 7,056 expression profiles for 1,309 distinct compounds. Genome-wide linear regression of each of the drug response expression profiles on the locus expression signatures was performed (see SI Materials and Methods for details). We constructed networks containing locus-TF-drug associations using the following procedure. First, we selected the drug/locus combinations whose expression signatures are negatively associated with each other. Then, we connected both the locus and the drug to the TFs whose promoter affinities were significantly associated both with the corresponding expression signature. To connect drugs to TFs, we applied genome-wide linear regression between drug response profiles and TF binding affinities (see SI Materials and Methods for details).
